Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides (NCT05357794)

🧪 Interventions in This Study

• Brentuximab vedotin (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Biopsy-confirmed mycosis fungoides in stage I-IV (APPENDICES 3 AND 4); the presence of Sezary cells in the blood is acceptable at original diagnosis or at enrollment into the protocol, as long as the patient has current mycosis fungoides in the skin and the sesary cells in peripheral blood are \< 1000 cells/ microlitre at the time of enrollment.
2. Participants with relapsed/ refractory mycosis fungoides expressing at least 1% CD30 are eligible.
3. Previous systemic anticancer therapy must have been discontinued at least 1 week before treatment
4. In the case of myelosuppressive chemotherapy treatment may start once counts have recovered including absolute WBC\> 1000, platelets\> 50K.
5. Topical or systemic steroids (equivalent to 10 mg/day of prednisone) may be considered if the dose of such steroids has been constant and their discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/or unnecessary suffering, after discussion with the Principal Investigator.
6. 18 years of age or older
7. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 3 (APPENDIX 5)
8. No required wash-out period for prior therapies
9. HIV+ participants must be on stable antiretroviral treatment for 12 weeks before the first day of cycle 1 (C1D1), with CD4 count \>200 within the 7 days before C1D1.
10. Ability to understand and the willingness to sign a written informed consent document.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• MD Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (713) 563-2406

Email: bdabaja@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Mycosis Fungoides

• ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome — Duarte, California
• Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome — Basking Ridge, New Jersey
• Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides — Chicago, Illinois
• A Study of VG712 in Patients With Mycosis Fungoides — Tampa, Florida
• Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients — Stanford, California

Explore by condition: All Mycosis Fungoides clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.